Literature DB >> 11641832

Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus.

V Soriano, L Martín-Carbonero, J García-Samaniego, M Puoti.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11641832     DOI： 10.1086/323009

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  9 in total

1.  Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.

Authors:  Valrie Martinez; Thi Dieu Ngan Ta; Zahra Mokhtari; Marguerite Guiguet; Patrick Miailhes; Marc-Antoine Valantin; Frderic Charlotte; Philippe Bertheau; Jean-Michel Molina; Christine Katlama; Eric Caumes
Journal:  BMC Res Notes       Date:  2012-07-09

2.  Inpatient health services utilization among HIV-infected adult patients in care 2002-2007.

Authors:  Baligh R Yehia; John A Fleishman; Perrin L Hicks; Michelande Ridore; Richard D Moore; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2010-03       Impact factor: 3.731

3.  Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999.

Authors:  Dawn K Smith; Lytt I Gardner; Ruby Phelps; Merle E Hamburger; Charles Carpenter; Robert S Klein; Ann Rompalo; Paula Schuman; Scott D Holmberg
Journal:  J Urban Health       Date:  2003-12       Impact factor: 3.671

4.  Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons.

Authors:  Nancy Crum-Cianflone; Gary Collins; Sheila Medina; Dean Asher; Richard Campin; Mary Bavaro; Braden Hale; Charles Hames
Journal:  Clin Gastroenterol Hepatol       Date:  2009-10-02       Impact factor: 11.382

Review 5.  Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection.

Authors:  Seth D Crockett; Emmet B Keeffe
Journal:  Ann Clin Microbiol Antimicrob       Date:  2005-09-13       Impact factor: 3.944

6.  Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.

Authors:  Giorgiana Hatu; François Bailly; Emmanuel Pourcelot; Pierre Pradat; Patrick Miailhes; Marianne Maynard; François Parant; Pierre Chiarello; Jean-Michel Livrozet; Fabien Zoulim; Marie-Claude Gagnieu
Journal:  BMC Infect Dis       Date:  2014-03-20       Impact factor: 3.090

7.  Lack of Association Between Recent Cannabis Use and Advanced Liver Fibrosis Among HIV-positive Heavy Drinkers.

Authors:  Daniel Fuster; Kaku So-Armah; Debbie M Cheng; Sharon M Coleman; Natalia Gnatienko; Dmitry Lioznov; Evgeny M Krupitsky; Matthew S Freiberg; Jeffrey H Samet
Journal:  Curr HIV Res       Date:  2021       Impact factor: 1.341

8.  Severe morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine Cohort.

Authors:  Mojgan Hessamfar; Céline Colin; Mathias Bruyand; Madeleine Decoin; Fabrice Bonnet; Patrick Mercié; Didier Neau; Charles Cazanave; Jean-Luc Pellegrin; François Dabis; Philippe Morlat; Geneviève Chêne
Journal:  PLoS One       Date:  2014-07-30       Impact factor: 3.240

9.  A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients.

Authors:  Massimo Puoti; Barbara Zanini; Gian Paolo Quinzan; Laura Ravasio; Giuseppe Paraninfo; Teresa Santantonio; Adriano Rollo; Stefania Artioli; Franco Maggiolo; Serena Zaltron; Enzo Raise; Ermenegildo Mignani; Francesco Resta; Gabriella Verucchi; Giuseppe Pastore; Fredy Suter; Giampiero Carosi
Journal:  J Hepatol       Date:  2004-08       Impact factor: 25.083
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.